Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients (ImmunoDual)
Rationale: Chronic HCV infection is characterised by a weak HCV specific CD8+ T cell response, due to continuous pressure of high viral load. Treatment of chronic HCV patients with ASV and DCV will result in a significant drop in HCV viral load. At present, no information is available on the immunological effects of treatment with ASV and DCV, nor on the early effects of viral load reduction caused by a compound that is thought not to possess direct immunomodulatory effects. This information will be crucial for a better understanding of the mechanisms that may limit the effectiveness of treatment, occurrence of viral rebound or relapses during, at the end of treatment or during the follow up period.
Objective: To evaluate in detail the functionality of immune cells in blood in chronic HCV patients before, during and after treatment with ASV and DCV, in an IFN-free regimen.
Study design: This is an investigator-initiated single center open label study with one arm of 12 patients.
Study population: Adult chronic HCV patients with genotype 1b, who are previous non-responders to the treatment.
Intervention (if applicable): All patients will be treated with twice daily a 200 mg oASV and once daily a 60 mg DCV for 24 weeks.
Main study parameters/endpoints:
- Phenotype and function of blood leukocytes during treatment; frequency of HCV-specific T cells, NK cells and monocytes
- Gene expression levels of leukocyte populations before, during and after treatment
- Gene expression levels of the type I IFN signaling pathway on whole blood samples
- Serum cytokines levels using multiplex platforms
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
-
Rotterdam、オランダ、3015 CE
- Erasmus Medical Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patients between 18 and 70 years of age, with a chronic hepatitis C - genotype 1b infection
- Patients are non-responders to previous treatment with peginterferon or conventional interferon plus ribavirin combination therapy
- High viral load (>400,000 IU/ml)
- Indication for antiviral therapy of hepatitis C according to current clinical guidelines
- Written informed consent
Exclusion Criteria:
- Decompensated cirrhosis (Child-Pugh Grade B or C)
- Hepatic imaging (ultrasound, CT or MRI) with the evidence of hepatocellular carcinoma within the last 3 months.
- Females who are pregnant or breast-feeding
- History or other evidence of severe illness, malignancy or any other condition which would make the patient, in the opinion of the investigators, unsuitable for the study
- Co-infections with human immunodeficiency virus (HIV) or Hepatitis B virus (HBV)
- Presence of contra-indications for antiviral therapy with ASV and DCV:
- Interfering substance abuse, such as high alcohol intake (indicator: 28 drinks/ week)
- Any exposure to NS3 protease inhibitors or NS5A polymerase inhibitors
- Treatment with peginterferon/ ribavirin within 6 months before start of therapy
- Any other condition which in the opinion of the investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating and completing in the study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:Daclatasvir and asunaprevir
daclatasvir 60 mg once daily asunaprevir 100 mg BID
|
60 mg once daily
100 mg BID
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
---|---|
HCV-specific T cell phenotype and function (a composite measure of (I) HCV-specific T-cell frequency and (II) phenotypic expression of memory markers and (III) inhibitory receptor markers
時間枠:1 year
|
1 year
|
NK cell phenotype and function (a composite measure of (I) NK cell frequency and (II) expression of activation and inhibitory markers (III) IFN-y production upon IL-12/IL-18 stimulation and (IV) Perforin granzyme production
時間枠:1 year
|
1 year
|
二次結果の測定
結果測定 |
時間枠 |
---|---|
Gene expression levels of the type I IFN signaling pathway on whole blood samples measured by multiplex
時間枠:1 year
|
1 year
|
Gene expression levels of leukocyte populations before, during and after treatment measured by microarray
時間枠:2 years
|
2 years
|
Serum cytokines levels using multiplex platforms LUMINEX -100
時間枠:1 year
|
1 year
|
協力者と研究者
捜査官
- 主任研究者:Rob de Knegt, M.D.、Erasmus MC
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
慢性C型肝炎の臨床試験
-
Dokuz Eylul UniversityEge University完了MMP9 | TIMP1 | MMP9 -1562 C/T | TIMP1 372 T/C七面鳥
-
Tripep ABInovio Pharmaceuticalsわからない
-
Hadassah Medical OrganizationXTL Biopharmaceuticals引きこもった
-
Beni-Suef University完了
-
Humanity and Health Research CentreBeijing 302 Hospital完了
-
Trek Therapeutics, PBC完了慢性C型肝炎 | C型肝炎遺伝子型1 | C型肝炎(HCV) | C型肝炎ウイルス感染症アメリカ, ニュージーランド
-
Trek Therapeutics, PBC完了慢性C型肝炎 | C型肝炎(HCV) | C型肝炎遺伝子型4 | C型肝炎ウイルス感染症アメリカ
-
Meir Medical Center完了デジタルステレオ光ディスク画像からC/D比を測定する新しい技術を開発 | C/D 測定の観察者内再現性 | C/D 測定値の観測者間のばらつき
Daclatasvirの臨床試験
-
ANRS, Emerging Infectious Diseases完了
-
Mansoura Universityわからない